Nubeqa
| Chemical Name | darolutamide |
| Dosage Form | Tablet (oral; 300 mg) |
| Drug Class | Androgen receptor inhibitors |
| System | Multiple |
| Company | Bayer |
| Approval Year | 2019 |
Indication
- For the treatment of patients with non-metastatic castration-resistant prostate cancer.
More on this drug: Clinical Trials
| Document Title | Year | Source |
| Nubeqa (darolutamide) Prescribing Information. | 2022 | Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ |
| Androgen receptor signaling inhibitors in addition to docetaxel with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis. | 2022 | European Urology |
| Document Title | Year | Source |
| Darolutamide with androgen deprivation therapy for treating non-metastatic hormone-relapsed prostate cancer. | 2020 | NICE |
| Darolutamide (Nubeqa) nmCRPC – Final economic guidance report. | 2020 | CADTH |
| Darolutamide (Nubeqa) nmCRPC – Final clinical guidance report. | 2020 | CADTH |
| Assessment report: Nubeqa. | 2020 | EMA |
| Australian public assessment report for darolutamide. | 2020 | Australian Government: Department of Health |
| Document Title | Year | Source |
| Advanced prostate cancer: AUA/ASTRO/SUO guideline. | 2020 | American Urological Association Education and Research |
| Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. | 2020 | Annals of Oncology |